Leadership shakeup as HeartBeam (NASDAQ: BEAT) reorganizes for global ECG push
Rhea-AI Filing Summary
HeartBeam, Inc. announced a strategic reorganization and leadership transition centered on accelerating global adoption of its ambulatory ECG signal platform and improving capital efficiency. Chief Executive Officer and director Robert P. Eno will depart effective June 30, 2026, and is expected to move into a consulting role under his existing employment agreement, subject to a release of claims.
Founder and President Branislav Vajdic, Ph.D. will serve as principal executive officer effective July 1, 2026, while operations are aligned around focused implementation teams led by Dr. Vajdic and Executive Chairman Rich Ferrari. Director Mark Strome resigned from the Board on June 18, 2026; both his resignation and Mr. Eno’s departure are stated as not due to disputes or disagreements with the company.
The company highlights that its 3D ambulatory ECG platform, including 3D signal capture and 12‑lead ECG synthesis, has received FDA clearance for arrhythmia assessment, and it plans to continue clinical studies to expand its technology for heart attack and other cardiac conditions while targeting a meaningfully lower cost structure.
Positive
- Regulatory progress: HeartBeam’s 3D ECG technology and 12‑lead ECG synthesis software have received FDA clearance for arrhythmia assessment, supporting commercialization of its ambulatory cardiac monitoring platform.
Negative
- Leadership turnover: The mutual departure of CEO and director Robert P. Eno and the immediate resignation of director Mark Strome represent significant leadership changes occurring alongside a major reorganization.
- Reorganization risk: The shift to a new operating structure aimed at a lower cost base and accelerated execution may create near-term execution and integration risk as responsibilities are redistributed.
Insights
HeartBeam pairs a CEO change with a cost-focused strategic reorganization.
HeartBeam is shifting from a traditional CEO-led structure to focused implementation teams overseen by Founder/President Branislav Vajdic and Executive Chairman Rich Ferrari. CEO Robert P. Eno exits these roles on June 30, 2026 but is expected to remain as a consultant.
This move is framed around global commercialization of its ambulatory ECG platform and a “meaningfully lower cost structure.” Two FDA clearances for arrhythmia assessment, in December 2024 and December 2025, support the commercialization narrative, while the company continues clinical studies to broaden indications.
Leadership transitions plus Board member Mark Strome’s resignation introduce governance change alongside the reorganization. The long-term impact will depend on how effectively the new operating structure converts these regulatory milestones into sustained adoption and revenue, details of which are not quantified in this disclosure.
8-K Event Classification
Key Figures
Key Terms
Emerging growth company regulatory
FDA marketing clearance regulatory
arrhythmia assessment medical
forward-looking statements regulatory
principal executive officer financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of Registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Robert P. Eno Departure
On June 18, 2026, Heartbeam, Inc. (the “Company”) and Mr. Eno mutually agreed to his departure as the Company’s Chief Executive Officer, as a member of the Company’s Board of Directors (the “Board”), and as the Company’s principal executive officer, effective as of June 30, 2026, in connection with a strategic reorganization within the Company. Mr. Eno’s decision to depart is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Eno’s departure, it is expected that he and the Company will enter into a consulting agreement whereby Mr. Eno is expected to provide support services to the Company following June 30, 2026, in an advisory capacity. Any payment of the severance amounts pursuant to the terms of Mr. Eno’s Employment Agreement dated as of January 17, 2023 (the “Employment Agreement”) is subject to Mr. Eno’s execution of a release of claims satisfactory to the Company. The description of Mr. Eno’s Employment Agreement is qualified in its entirety by reference to the full text of the Employment Agreement, which is included as Exhibit 10.2 to the Current Report on Form 8-K filed by the Company on January 18, 2023.
Until a new Chief Executive Officer is identified, the Company will strategically align its operations around focused implementation teams led by Branislav Vajdic, Ph.D., Founder and President, and Rich Ferrari, Executive Chairman of the Board. Dr. Vajdic, will also serve as the Company’s principal executive officer, effective July 1, 2026.
Biographical information and information regarding related party transactions with respect to Dr. Vajdic and Mr. Ferrari is contained in Part III, Items 10 and 13 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which Items are incorporated by reference herein.
Mark Strome Resignation
On June 18, 2026, Mark Strome notified the Company of his resignation from the Board and all committees thereof, effective immediately. Mr. Strome's resignation was not due to any dispute or disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
Item 8.01 Other Events.
On June 24, 2026, the Company issued a press release announcing the departure of Mr. Eno as the Company’s Chief Executive Officer, a member of the Board and principal executive officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 8.01, including the related information set forth in the press release attached hereto as Exhibit 99.1, is being “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
- 1 -
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release of HeartBeam, Inc. issued on June 24, 2026 (furnished herewith) | |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| HeartBeam, Inc. | ||
| Date: June 24, 2026 | By: | /s/ Branislav Vajdic |
| Name: | Branislav Vajdic | |
| Title: | President | |
- 3 -
Exhibit 99.1
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
| ● | Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales |
| ● | Advancing toward heart attack detection as a key expansion of the platform |
| ● | Tailoring its technology to fit each market, while operating with a leaner, more focused structure |
| ● | Company to provide more details on strategy as part of Second Quarter 2026 conference call in August |
SANTA CLARA, CA - June 24, 2026 - HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operations around focused implementation teams which will be led by Branislav Vajdic, Ph.D., Founder and President, and Rich Ferrari, Executive Chairman. The teams are focused on a single goal: to provide every at-risk cardiac patient access to HeartBeam’s groundbreaking technology.
This structure streamlines decision-making, improves accountability, and enables leadership to concentrate resources on achieving key milestones while maintaining disciplined management. The reorganization is expected to sharpen the Company’s focus on delivering results and create a meaningfully lower cost structure. As part of these changes, Robert Eno, former Chief Executive Officer, will transition to a consulting role for HeartBeam.
“Our mission is to drive widespread global adoption of our breakthrough technology,” said Ferrari. “We thank Rob for bringing HeartBeam to this point, from securing FDA clearances to establishing the commercial foundation that makes this next phase possible. Now, we are streamlining our operations and broadening our reach so that this potentially life-changing system can get into the hands of as many patients as possible, as quickly as possible.”
The reorganization will enable the company to focus on the key deliverables which separate it from the crowded cardiac monitoring space, namely:
| ● | An AI-ready signal, built for more than cardiac care. AI can only deliver actionable insight based on the quality of the signal it is given. HeartBeam has built what it believes is the best ambulatory ECG signal-acquisition platform — a data-rich 3D signal that is the input AI needs to move from inference to true detection. This broader platform strategy has been made possible most recently by the rapid advance of AI: the Company can now extract remarkably accurate, clinical-grade recordings directly from its groundbreaking 3D signal-acquisition and ECG processing platform — turning more than a decade of signal science into an immediately actionable foundation. Moreover, the company believes this same signal quality can serve third-party AI platforms being developed across medicine that depend on high-quality, real-world ECG data. |
| ● | Advancing toward heart attack detection. A central focus of this strategy is expanding HeartBeam’s platform beyond arrhythmia assessment into reliable heart attack detection, which the company believes is one of the largest unmet needs in cardiac care. The company continues to build the evidence base needed to pursue this expanded indication and believes this milestone will make its device a must-have for every cardiac patient, with the potential to save millions of lives and billions of dollars in avoidable medical costs. |
| ● | One platform, every market. HeartBeam intends to achieve global adoption by partnering its breakthrough patented 3D ECG platform across the five channels that already have distribution — governments and national health systems, ECG OEMs, Holter and patch manufacturers, health systems and integrated delivery networks, and consumer wearable companies — and by adapting its technology to the form factor each use case requires. The company believes its technology can be adapted to multiple form factors: a ruggedized unit that lets a rural health clinic triage a patient in minutes, an adhesive patch for longer-term monitoring, a simpler form factor for an older or less agile patient, or a sleek, compact card an expert user slips into a wallet. |
The company received FDA marketing clearance for its synthesized 12-lead ECG signal for arrhythmia assessment in December 2025 giving physicians a familiar format they already trust. The company believes this unique capability will be critical to adoption in many use cases.
“HeartBeam’s technology addresses a fundamental gap in cardiac care: the ability to get a verified, clinical-grade ECG reading anywhere, at any time, without a clinic visit. With commercialization underway, the company is positioned to make that capability routine for the millions of Americans living with or at risk for arrhythmia,” said Dr. Vajdic. “At the same time, we will continue to conduct the previously announced clinical studies to accelerate the development of our offering into a comprehensive detection platform for heart attack and other cardiac conditions beyond arrhythmia.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
1Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The heart attack detection indication and algorithm are not FDA cleared and not available in the US or any other geography at this time. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.